Phylogenetic tests of the hypothesis of block duplication of homologous genes on human chromosomes 6, 9, and 1

There are 10 gene families that have members on both human chromosome 6 (6p21.3, the location of the human major histocompatibility complex [MHC]) and human chromosome 9 (mostly 9q33-34). Six of these families also have members on mouse chromosome 17 (the mouse MHC chromosome) and mouse chromosome 2. In addition, four of these families have members on human chromosome 1 (1q21-25 and 1p13), and two of these have members on mouse chromosome 1. One hypothesis to explain these patterns is that members of the 10 gene families of human chromosomes 6 and 9 were duplicated simultaneously as a result of polyploidization or duplication of a chromosome segment ("block duplication"). A subsequent block duplication has been proposed to account for the presence of representatives of four of these families on human chromosome 1. Phylogenetic analyses of the 9 gene families for which data were available decisively rejected the hypothesis of block duplication as an overall explanation of these patterns. Three to five of the genes on human chromosomes 6 and 9 probably duplicated simultaneously early in vertebrate history, prior to the divergence of jawed and jawless vertebrates, and shortly after that, all four of the genes on chromosomes 1 and 9 probably duplicated as a block. However, the other genes duplicated at different times scattered over at least 1.6 billion years. Since the occurrence of these clusters of related genes cannot be explained by block duplication, one alternative explanation is that they cluster together because of shared functional characteristics relating to expression patterns.      

Metazoan parasite species in cultured mussel Mytilus galloprovincialis in the Thermaikos Gulf (North Aegean Sea, Greece)

This is the first study on parasites of cultured Mytilus galloprovincialis L. in Greek waters, and is based on samples collected every 2 to 3 mo between September 2000 and November 2001 at 3 stations in the Thermaikos Gulf. Each sample comprised 40 mussels. We found 4 metazoan parasite species: hydroid Eugymnanthea inquilina, gill turbellarian Urastoma cyprinae, trematode Proctoces maculatus and gut copepod Mytilicola intestinalis. Of 840 mussels examined, 406 (48.3%) mussels were harbouring hydroids of E. inquilina, 278 (33.1%) were infested with U. cyprinae, 94 (11.2%) were infested with M. intestinalis, and only 7 (0.8%) were infested with P. maculatus. The prevalence and intensity of these parasites were related to temperature and pollution. Mussels infested with these parasites had significantly lower condition indices than non-infested mussels; larger mussels were more often infested than smaller ones.     

Progesterone inhibition of maternal behavior in the rat

The present series of experiments investigated the role of progesterone in inhibiting the onset of maternal behavior in the rat. Female rats hysterectomized and ovariectomized on Day 16 of pregnancy and injected subcutaneously with 20 μg/kg of estradiol benzoate (EB) show a short latency to onset of maternal behavior when presented with test pups 48 hr later. A subcutaneous injection of either 1 or 5 mg of progesterone on Day 16 of pregnancy and again 24 hr later inhibited this EB-induced short-latency onset of maternal behavior. The central neural site at which progesterone might act to produce this inhibitory effect was explored. Famale rats, hysterectomized and ovariectomized on Day 16 of pregnancy and injected subcutaneously with EB, received implants of crystalline progesterone on Day 16 of pregnancy into either the medial preoptic area, ventromedial hypothalamus, midbrain tegmentum, dorsal raphe nucleus, or median raphe nucleus. No inhibitory effects were found and all females showed a short-latency onset of maternal behavior. Several possible explanations for this lack of inhibitory effect of intracerebral implantation of progesterone are discussed.     

Neurofeedback Intervention in Fibromyalgia Syndrome; a Randomized,Controlled, Rater Blind Clinical Trial

We designed a randomized, rater blind study to assess the efficacy of EEG Biofeedback (Neurofeedback-NFB) in patients with fibromyalgia syndrome (FMS). Eighteen patients received twenty sessions of NFB-sensory motor rhythm (SMR) treatment (NFB group) during 4 weeks, and eighteen patients were given 10 mg per day escitalopram treatment (control group) for 8 weeks. Visual Analog Scales for pain and fatigue, Hamilton and Beck Depression and Anxiety Inventory Scales, Fibromyalgia Impact Questionnaire and Short Form 36 were used as outcome measures which were applied at baseline and 2nd, 4th, 8th, 16th, 24th weeks. Mean amplitudes of EEG rhythms (delta, theta, alpha, SMR, beta1 and beta2) and theta/SMR ratio were also measured in NFB group. All post-treatment measurements showed significant improvements in both of the groups (for all parameters p < 0.05). NFB group displayed greater benefits than controls (for all parameters p < 0.05). Therapeutic efficacy of NFB was found to begin at 2nd week and reached to a maximum effect at 4th week. On the other hand, the improvements in SSRI treatment were also detected to begin at 2nd week but reached to a maximum effect at 8th week. No statistically significant changes were noted regarding mean amplitudes of EEG rhythms (p > 0.05 for all). However, theta/SMR ratio showed a significant decrease at 4th week compared to baseline in the NFB group (p < 0.05). These data support the efficacy of NFB as a treatment for pain, psychological symptoms and impaired quality of life associated with fibromyalgia.     

Bone marrow suppression and severe anaemia associated with persistent Plasmodium falciparum infection in African children with microscopically undetectable parasitaemia

In sub-Saharan Africa the highest overlap between malaria and HIV infections occurs in female adolescents. Yet control activities for these infections are directed to different target groups, using disparate channels. This reflects the lack of priority given to adolescents and the absence of an accepted framework for delivering health and health-related interventions to this high-risk group. In this paper it is argued that female adolescents require a continuum of care for malaria and HIV – prior to conception, during and after pregnancy and that this should be provided through adolescent services. The evidence for this conclusion is presented. A number of African countries are commencing to formulate and implement adolescent-friendly policies and services and disease control programs for malaria and HIV will need to locate their interventions within such programs to ensure widespread coverage of this important target group. Failure to prioritize adolescent health in this way will seriously limit the success of disease control programs for malaria and HIV prevention.